摘要
研究表明,肥胖与卵巢癌的发生和预后有关,而高血糖状态是营养过剩、超重和肥胖的病理特征,并且是肿瘤发生和不良预后的独立危险因子,高血糖负荷和高血糖指数增加卵巢癌的危险。肥胖和糖代谢异常可能通过激活AMPK和mTOR相关的信号通路参与卵巢癌的发生和发展。因此应用mTOR抑制剂或二甲双胍抑制mTOR信号转导通路活性,在肥胖伴发的上皮性卵巢癌的治疗中将具有重要意义。文章就肥胖型卵巢癌异常糖代谢通路及针对信号通路靶点的靶向治疗作一综述。
Recent studies suggest that obesity is associated with the occurrence and prognosis of ovarian cancer, and hyperglycemia is a pathological feature of over nutrition, overweight and obe- sity. Also hyperglycemia is an independent risk factor of tumor occurrence and poor prognosis. High glycemic load and high glycemic index increase the risk of ovarian cancer. Obesity and ab- normal glucose metabolism may take part in the occurrence and development of ovarian cancer by activating AMPK and mTOR signaling pathway.The application of mTOR inhibitor and metformin inhibiting mTOR signaling pathway activity might have an important role in the treatment of ovar- ian cancer associated with obesity. In this paper,abnormal glucose metabolism pathway and target therapy aiming to signaling pathways of ovarian cancer are reviewed.
出处
《肿瘤学杂志》
CAS
2015年第11期870-874,共5页
Journal of Chinese Oncology
基金
国家自然科学基金(81372778)
关键词
卵巢肿瘤
糖代谢
AMPK信号通路
靶向治疗
ovarian neoplasms
glucose metabolism
AMPK signaling pathway
target therapy
